Sprengers E D
Thromb Haemost. 1986 Feb 28;55(1):74-7.
A polyclonal antibody raised against plasminogen activator (PA-)inhibitor from endothelial cells fully precipitates the PA-inhibitor in endothelial cell conditioned medium but only a part of the PA-inhibitory activity in blood plasma. This indicates that the PA-inhibitory activity in blood plasma is not due to a single inhibitory component. Performing the assay for PA-inhibitory activity in plasma both in the presence and absence of saturating concentrations of anti-endothelial cell PA-inhibitor antibodies, allows the determination of endothelial cell type PA-inhibitor in plasma. The assay gives a linear dose-response curve of amount of plasma added versus t-PA neutralised. Values for endothelial cell type PA-inhibitor in plasma of a group of 20 healthy individuals are in the range of 0.0-16.8 IU/ml and are not normally distributed (median value 3.0 IU/ml). This method also reveals a second, so far unidentified, PA-inhibitory component in human plasma.
一种针对内皮细胞纤溶酶原激活物（PA）抑制剂产生的多克隆抗体可完全沉淀内皮细胞条件培养基中的PA抑制剂，但只能沉淀血浆中部分PA抑制活性。这表明血浆中的PA抑制活性并非由单一抑制成分所致。在有和没有饱和浓度的抗内皮细胞PA抑制剂抗体存在的情况下，对血浆中的PA抑制活性进行测定，可确定血浆中内皮细胞型PA抑制剂的含量。该测定给出了添加血浆量与t-PA中和量的线性剂量反应曲线。一组20名健康个体血浆中内皮细胞型PA抑制剂的值在0.0 - 16.8 IU/ml范围内，且呈非正态分布（中位数为3.0 IU/ml）。该方法还揭示了人血浆中另一种迄今未明确的PA抑制成分。
